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Abstract
Ovarian cancer is particularly insidious in nature. Its ability to go undetected until late stages coupled with its non-
descript signs and symptoms make it the seventh leading cause of cancer related deaths in women. Additionally,
the lack of sensitive diagnostic tools and resistance to widely accepted chemotherapy regimens make ovarian can-
cer devastating to patients and families and frustrating to medical practitioners and researchers. Here, we provide
an in-depth review of the theories describing the origin of ovarian cancer, molecular factors that influence its
growth and development, and standard methods for detection and treatment. Special emphasis is focused on
interactions between ovarian tumors and the innate and adaptive immune system and attempts that are currently
underway to devise novel immunotherapeutic approaches for the treatment of ovarian tumors.
Ovarian cancer occurrence
Epithelial ovarian cancer (EOC) is the most deadly of
gynecological cancers and is the seventh-leading cause
of cancer deaths in women. In 2008, there were 21,650
cases reported which resulted in the deaths of 15,520
women in the United States [1]. Spread of the disease
within the peritoneal cavity is associated with non-speci-
fic clinical symptoms that are often mistaken for other
gastrointestinal or reproductive diseases. Some of the
most common symptoms are abdominal discomfort and
bloating. Other symptoms include vaginal bleeding, gas-
trointestinal discomfort, early satiety, and urinary tract
symptoms [2]. Another obstacle hindering diagnosis is
the fact that the ovaries are deep within the pelvic cavity
and difficult to palpate, especially in peri-post menopau-
sal women, the group with the highest incidence of the
disease. Because of these reasons, 70% of patients are
not diagnosed with the disease until the cancer has
metastasized beyond the ovaries and is at stage III or IV
[3]. However, studies surveying ovarian cancer patients
demonstrate that over 95% of EOC patients had abdom-
inal complaints for many months before their diagnosis
[4-6]. There is now a new initiative to quantify the
symptoms experienced by ovarian cancer patients prior
to diagnosis of the disease. A “Symptoms Index” has
been established and studies are underway to determine
if it can be used- either independently or in combina-
tion- with a molecular marker as a predictor of early
stage ovarian cancer [5,6].
There are several different types of ovarian cancers
depending upon the cell type of origin. Epithelial cell
ovarian cancer (EOC) constitutes 90% of ovarian can-
cers, while gonadal-stromal (6% occurrence), and germ
cell (4% occurrence) tumors make up the rest of the
incidence of ovarian cancer patients [7]. As ovarian can-
cer of epithelial cell origin is the most common type,
EOC is discussed throughout this review.
The majority of EOC cases are sporadic in nature and
occur in women with no known predisposing factors
and thus, in the general population, the overall risk of
EOC is low (2-5%). Only a small percentage (5-10%) of
EOC patients have a genetic predisposition to the dis-
ease. Ninety percent of these patients are carriers of
mutated BRCA1 and/or BRCA2 genes, which are also
implicated in hereditary breast cancer [8]. These genes
normally act as tumor suppressors and regulate cellular
proliferation and DNA repair by maintaining chromo-
some integrity. Mutations in these genes render the pro-
teins unable to perform their intended functions. The
lifetime risk of ovarian cancer for patients with BRCA1
mutations is 20% to 60%, and the risk for BRCA2 muta-
tion carriers is 10% to 35% [8]. Ovarian cancers asso-
ciated with germline mutations of BRCA1 appear to be
predominantly of serous type and age of the patient at
diagnosis is significantly less as compared to the
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mutation may elect to undergo prophylactic bilateral sal-
pingo-oophorectomy (removal of both fallopian tubes
and ovaries).
Origins of EOC
The normal ovarian surface epithelium (OSE) covers the
surface of the ovary. OSE is highly responsive to envir-
onmental stimuli, including those associated with ovula-
tion [11]. In a normal woman, OSE are a monolayered
squamous-to-cuboidal epithelium which functions to
shuttle molecules in and out of the peritoneal cavity, as
well as participates in the rupture and repair that
accompanies every ovulation [12]. These cells are mor-
phologically indistinct and histologically simple; there-
fore, it is difficult to understand how these cells can
transform into tumors [13]. The OSE derive from the
embryonic celomic epithelial cells which are a part of
the mesoderm. The fallopian tube, uterus, and endocer-
vix are derived from the Mullerian duct which is an
invagination of the celomic epithelium. It is hypothe-
sized that OSE cells retain the ability to differentiate
into four major histological subtypes, which could
explain the distinct histological EOC subtypes. There
are four common sub-types of EOC including serous
(fallopian tube-like), endometrioid (endometrium-like),
mucinous (endocervical-like), and clear cell (mesone-
phros-like) [12].
The differentiation of OSE cells from cuboidal epithe-
lial cells to a mesenchymal phenotype that is character-
istic of Mullerian duct-derived tissues is termed
epithelial- mesenchymal transition (EMT). The occur-
rence of EMT is postulated to aid cells in movement
during embryo tissue generation, tissue regeneration
after wounding, and is implicated in the development of
cancer [14]. OSE cells normally undergo EMT to heal
the wound that forms following ovulation. Uncommitted
OSE cells normally express keratin, which is associated
with an epithelial cell type [12]. However, these cells
also constitutively express vimentin, N-cadherin, and
smooth muscle alpha-actin, all of which are associated
with the mesenchymal phenotype [12]. OSE cells also
produce several proteolytic enzymes (which help to
degrade the epithelial cell wall during ovulation), as well
as secrete collagen type III, characteristics that are also
common to mesenchymal cells. OSE cells express low
levels of the mucin MUC16 (CA125). Mullerian-duct
derived tissues express high levels of MUC16 (CA125),
as do ovarian tumors [15]. As we will discuss later,
MUC16 (CA125) over expression in ovarian tumors is
an important marker for progression and regression of
EOC.
OSE cells undergo EMT transition after ovulation
to remodel the extracellular matrix and repair the
post-ovulatory wound that is generated during expulsion
of the oocyte. Epithelial cells are characteristically
polar and are bound together with molecules (such as
E-cadherin) that facilitate cell-cell junctions. Conversely,
the mesenchymal phenotype is that of motility and
movement, as well as reduced polarity of a cell [16].
The transition of OSE to a mesenchymal phenotype aids
in the ovulatory process because these converted cells
have increased motility, altered proliferative responses,
and the ability to remodel the extracellular matrix
(ECM) [17]. TGF-b, EGF, and collagen are all present at
the site of ovulatory rupture and can induce OSE EMT.
OSE cells also undergo EMT in collagen matrices. It is a
normal function of OSE to undergo EMT, therefore,
cancer may represent unregulated EMT [14].
The expression of markers that are associated with
those of Mullerian-duct derived tissue are found in
inclusion cysts, which are the site of many neoplasms.
OSE lining inclusion cysts express higher levels of EOC
markers MUC16 (CA125) and CA19-9 and is two to
three times more metaplastic in women with ovarian
tumors compared to OSE in normal ovaries [18]. The
hypothesis that EOC may derive from inclusion cysts is
based upon the incessant ovulation theory, first pro-
posed by Fathalla in 1971 [19]. This theory is based
upon epidemiological data that reveals that women on
birth control or who have been pregnant and/or breast-
feeding have decreased risk of ovarian cancer. Fathalla
suggested that wounds in the epithelium surrounding
the ovary caused by ovulation month after month can
cause increased inflammation and cell proliferation;
thereby increasing the chance for cells to form neo-
plasms. Higher ovulatory activity is associated with an
increased accumulation of inclusion cysts and invagina-
tions of the OSE, which provide a hospitable environ-
ment for tumor cell growth [20]. This concept is
supported by in vitro evidence in which ovarian surface
epithelial cells from both rats and mice have been con-
tinuously cultured, mimicking the constant damage and
repair that OSE undergo. In both species these in vitro
cells spontaneously transformed into cancerous cells
[21-23]. Another observation that supports the incessant
ovulation hypothesis is that studies have repeatedly
shown that oral contraceptive use (which prevents ovu-
lation) reduces ovarian cancer risk [24].
An alternative hypothesis related to that of incessant
ovulation is known as the gonadotropin hypothesis
[25-27]. High levels of gonadotropins initiate each ovu-
lation and persist immediately after menopause. These
hormones stimulate the ovulation-like process involving
the expression of cytokines and proteolytic enzymes
within the surface epithelium. I nflammatory factors
may lead to a loss of the basement membrane and the
formation of inclusion cysts which can contribute to cell
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(ewes) showed that oxidants released during ovulation
caused DNA fragmentation and apoptosis in cells that
were closest to the rupture, while milder DNA damage
and the accumulation of p53 was shown in decreasing
levels farther away from the rupture site [28].
Others hypothesize that ovarian tumors do not arise
from OSE at all, but derive directly from the Mullerian-
duct tissues and migrate to the ovarian surface. Dubeau
first proposed this hypothesis in 1999 [29]. According to
Dubeau, the theory which suggests that OSE cells must
first differentiate into Mullerian-duct type cells via
metaplasia before becoming neoplastic contradicts our
current understanding of cancer, which is that the can-
cerous cells are less differentiated than the cells they
originate from [30]. He suggests that a more likely sce-
nario is that EOC derives from Mullerian-duct derived
tissues, and has several compelling observations to sup-
port this hypothesis. Ovarian tumor cells share many
similar characteristics to the cells of the fallopian tubes,
uterus, and endocervix, and do not share histological or
protein expression profile with the OSE. Dubeau argues
that the fimbrae of the fallopian tubes, which literally
rub up against the surface of the ovary during ovulation
and sometimes adhere to the surface of the ovary due to
inflammation, are a prime site for the development of
metaplasia. The cells from the fimbrae of the fallopian
tubes have been shown to have developed pre-neoplastic
changes in women who have undergone surgery for pro-
phylactic removal of their fallopian tubes because of a
mutation in BRCA1 [31-33].
In addition to histological changes found in the fim-
brae of the fallopian tubes, mutations in the tumor sup-
pressor gene p53 in the distal fimbrae of women with
the BRCA
+ mutation have also been observed [34].
Christopher Crum’s group found strong p53 staining in
benign tissues from BRCA
+ women who underwent pro-
phylactic salpingo-oophorectomies. This staining corre-
lated with mutations in the p53 gene in these same
cells. Because the p53 mutations were found predomi-
nantly in the distal fimbrae of the fallopian tubes (the
cells that are in contact with the OSE), the location of
this staining may reveal one mechanism by which ovar-
ian tumors arise in BRCA
+ women [34]. In 2008,
Crum’s group correlated the p53 mutation in the fallo-
pian tube fimbrae with lower parity and increased age at
first childbirth, which links this marker to incessant
ovulation [35]. A comparison of p53 mutations in ovar-
ian inclusion cysts with p53 mutations in the fimbrae of
fallopian tubes, again from women who were BRCA
+
was conducted. The results revealed that p53 mutations
were not present in any inclusion cysts that were exam-
ined, but were present in 38% of fimbrae of fallopian
tubes from these women [36]. Another piece of evidence
to support the argument that EOC arises from the fallo-
pian tube is that several studies have shown that tumor
cells clinically identical to ovarian cancer cells are found
in the peritoneal environment in women years after
their ovaries have been removed for reasons other than
cancer [37-39].
Dubeau states that ovarian cancer is over-diagnosed,
and many of these cancers actually arise from the fallo-
pian tube or peritoneal cavity wall. The origin of ovarian
tumors is of important consideration, not only for
nomenclature reasons, but for women who have the
BRCA1 or BRCA2 mutation and are undergoing pro-
phylactic surgery and who want to preserve their ferti-
lity. If the origin of ovarian cancer is indeed not the
ovary, then the ovaries need not be removed, and cryo-
preservation of oocytes for future use is not an issue
[30].
Ovarian cancer detection
Attempts to find an accurate screening test for EOC
have, to date, been unsuccessful. CA125 (MUC16), ori-
ginally thought to be an indicator of ovarian cancer, is
now known to be quite non-specific as well as to lack
the sensitivity to detect stage I disease. Bast and cowor-
kers showed in the 1980s that CA125 was expressed in
the serum of the majority of patients with EOC, as well
as patients with cancer of the endometrium, fallopian
tube, and endocervix [40-44]. CA125 serum levels are
elevated in 80% of advanced stage EOC patients; how-
ever, this marker can be elevated in a variety of benign
conditions and other non-gynecologic malignancies.
High concentrations are found in pancreatic, breast,
bladder, liver, and lung cancers, as well as benign
diseases such as diverticulitis, uterine fibroids, endome-
triosis, benign ovarian cyst, tubo-ovarian abscess,
hyperstimulation syndrome, and ectopic pregnancies
[42,45-48]. Elevated levels are also found in physiological
conditions including both normal pregnancy and men-
struation [49]. Furthermore, CA125 levels are elevated
in less than half of the cases in early-stage ovarian can-
cers, underscoring the lack of sensitivity to diagnose
curable disease. Therefore, CA125 is not used as a
screening test, but mainly as a measure of disease pro-
gression, regression, and predictor of recurrence during
treatment for EOC. CA125 levels measured over a per-
iod of time along with transvaginal sonography has been
shown to increase sensitivity [50], however, the cost of
transvaginal screening limits its use in the general popu-
lation. CA125 itself is a repeating peptide epitope on the
large molecular weight mucin, MUC16 [51-54]. This
mucin is expressed at low levels by normal ovarian sur-
face epithelium and is overexpressed by EOC tumor
cells [43,49]. Tumor cells secrete MUC16 into the peri-
toneal fluid (PF) and from the abdominal cavity this
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detected via the CA125 serum assay.
Proteomic approaches are being utilized to identify
molecular markers for ovarian cancer and mathematical
models are being developed to identify specific patterns
that are indicative of disease [55]. Other promising mar-
kers for ovarian cancer include human epididymis pro-
tein-4 (HE4), decoy receptor-3 (DcR3), osteopontin,
mesothelin, spondin-2, SMRP, CA72-4, ERBB2, inhibin,
activin, EGFR, and lysophosphatidic acid, [50,56-66]. Of
these the most promising is HE4 which is expressed on
ovarian tumor cells from some patients that do not
express CA125. Indeed, studies have shown that the
combined monitoring of serum levels of CA125 and
HE4 is likely to significantly improve the sensitivity for
detection of ovarian cancer in women with pelvic mass
[67]. An important study published recently has con-
cluded that a steady increase in the serum concentra-
tions of CA125, HE4, and mesothelin can be detected in
patients up to 1-3 years before a clinical diagnosis of
ovarian cancer is made in patients [68].
Ovarian cancer staging and treatment
Ovarian cancer is a surgically staged disease, meaning
that it is impossible to tell what the stage of the cancer
is without examining the extent of the metastasis surgi-
cally. Metastasis of ovarian cancer spreads by direct
extension to neighboring organs from the ovaries or by
the sloughing of tumor cells into the peritoneal cavity.
These individual or groups of exfoliated cells float in the
fluid of the peritoneal cavity and can subsequently bind
to the wall of the peritoneal cavity and form additional
lesions. The tumor cells also commonly disseminate by
lymphatic spread [69]. Proper surgical staging requires a
complete inspection of the peritoneal cavity and its con-
tents, as well as evaluation of the retroperitoneal spaces
a n dl y m p hn o d e s .A tt h es a m et i m et h a tt h eE O C
patient is being evaluated for the stage of the disease,
the surgeon also attempts to remove all visible tumors
from within the peritoneal cavity. Additionally, the sur-
geon washes the peritoneal cavity several times with sal-
ine in order to remove as many tumor cells as possible.
This procedure is termed cytoreductive surgery or
tumor debulking [70].
The stages (I-IV) of ovarian cancer are determined by
the extent of metastasis. Stage I EOC is confined to the
ovaries whereas stage II affects other pelvic structures.
In stage III, the disease has spread beyond the pelvis
into the upper abdominal cavity or into the draining
nodal beds irrespective of peritoneal based disease. Stage
IV is defined as disease outside of the peritoneal cavity
and most commonly includes parenchymal liver lesions
or malignant pleural effusions. Patients with stage I dis-
ease most commonly undergo bilateral oophorectomy,
hysterectomy, and surgical staging including peritoneal
biopsies, omentectomy, and pelvic and aortic lymph
node dissection. In select cases of younger patients who
wish to preserve fertility, only the affected ovary may be
r e m o v e da n dah y s t e r e c t o m yw o u l dn o tb ep e r f o r m e d
[70]. Chemotherapy treatment in early stage disease is
dependent upon the grade of the tumor. It is recom-
mended that patients with advanced stage (II, III or IV)
EOC undergo cytoreductive surgery to remove all visible
tumor whenever feasible, followed by platinum and tax-
ane based chemotherapy [70]. Despite a high rate of
initial remission, these patients have a high rate of
recurrence (at least 50%) and overall poor survival. Can-
cer diagnosed in early stages has a much higher 5-year
survival rate (Stage I: >90%, Stage II: 70-80%) compared
to cancer diagnosed in later stages (Stage III: 20-30%,
Stage IV: <5%) [70]. A major advance in the treatment
of ovarian cancer has come from intraperitoneal admin-
istration of platinum and taxane agents instead of the
more conventional intravenous delivery of these drugs
[71-73]. Of the 654 randomized patients included in one
trial, the median survival for patients receiving intraperi-
toneal cisplatin was 49 months compared to 41 months
for the cohort receiving intravenous cisplatin [73].
Increased cytotoxicity remains a major hurdle curtailing
the efficacy of intraperitoneal chemotherapy [74].
Treatment is made difficult for EOC patients because
metastasis is acute and tumor cells exert immunosup-
pressive effects. The anatomical location of the ovaries
within the peritoneal cavity facilitates metastasis because
tumor cells can spread by sloughing off of the main
tumor and binding to many organs in the vicinity,
including the peritoneal cavity surfaces and the highly
vascular omentum [75]. This complicates treatment in
that it is technically impossible to remove all cancerous
cells during cytoreductive surgery. The accumulation of
peritoneal fluid in ovarian cancer patients also contri-
butes to metastasis by aiding the flow of tumor cells
within the peritoneal cavity. Peritoneal fluid contains
secretions from the tumor cells that have now been
shown to contain many factors which aid in the inhibi-
tion of the immune system in these patients [76-83].
Furthermore, ovarian tumors also acquire resistance to
chemotherapy. Spheroids, or clumps of tumor cells
(extremely common in the peritoneal fluid of EOC
patients), have been shown to be more resistant to che-
motherapy [84]. De novo and acquired chemoresistance
combined with expression of immunosuppressive factors
makes it difficult to effectively treat ovarian cancer
[85,86].
Tumorigenesis and Metastasis
Tumorigenesis requires several genetic alterations, either
somatic or inherited, that confer a selective growth
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tumor development, initial random genetic alterations
result in a tumor cell population with a proliferative
advantage. These tumor cells become the progenitors of
a clonal population that eventually dominates the tumor
mass. Tumor progression is analogous to Darwinian
selection, with repeated mutations and subsequent dom-
inance of the daughter cell population via expression of
traits that confer a survival advantage [86].
A defining characteristic of a malignant epithelial
tumor is invasion beyond the basement membrane into
the surrounding stromal tissues. For example, in breast
disease benign tumors such as fibrocystic lesions, sclero-
sis adenoma, and fibroadenoma are all characterized by
disorganization of the normal epithelial architecture.
However, no matter how extensive this disorganization
may become, these benign lesions are always character-
ized by a continuous basement membrane that separates
the neoplastic epithelium from the stroma [87]. Malig-
nant tumors are characterized by their ability to invade
through the basement membrane after which it is
impossible to determine how many cells have escaped
from the primary tumor and have established at meta-
static sites [88]. Similar to malignant invasion some
non-cancerous cells can physiologically invade basement
membranes. Common examples of this include migra-
tion of immune cells during an inflammatory response,
endothelial cells during an angiogenic response, and tro-
phoblasts into the endometrial stroma and blood vessels
to establish contact with the maternal circulation during
placentation. The mechanisms used by these cells are
thought to be very similar to those used by invading
tumor cells [88,89]. The difference between these nor-
mal functions and the invasion associated with tumor
cells is the lack of regulation seen in cancer. The
mechanisms for the regulation of invasiveness are yet
undetermined. Development of novel therapeutic agents
towards these factors could help treat inflammatory, and
angiogenesis disorders, as well as cancer formation [88].
Once a tumor is established metastasis may occur.
While primary tumors are usually successfully elimi-
nated by surgical or chemotherapeutic means, metas-
tases are more difficult to detect and treat [89].
Metastases can cause death via paraneoplastic syn-
dromes, interference with the normal functioning of an
organ because of a growing lesion, or from complica-
tions related to treatment [89].
EOC was originally thought to be of the linear-clonal
model of metastasis, which states that a late stage clone
of the tumor acquires an additional genetic change that
enables metastatic progression [90]. However, metastasis
m a yn o tb et h ef i n a ls t a g eo fc l o n a le v o l u t i o nd u r i n g
tumor progression. Some cells seem to have derived from
early stage clones in the primary tumor while others
derive from later stage clones. This group supports a
model in which primary ovarian cancers have a common
clonal origin but become polyclonal with different clones
at both early and late stages of genetic divergence acquir-
ing the ability to progress to metastasis [90].
The complexity of metastasis increases when one con-
siders that each cancer type typically metastasizes to dif-
ferent areas in the body. This is termed the “seed vs.
soil” hypothesis which was first observed by Stephen
Paget in 1889 [91]. Referring to the tumor cell as the
seed and a potential metastatic site as the “soil,” he sta-
ted, “When a plant goes to seed, the seeds are scattered
in all different directions; but they can only live and
grow if they land on congenial soil.” He hypothesized
that this theory could be used to predict metastatic loca-
tions for different cancers. Different selective pressures
exist in different organs and the tumor cells must adapt
to these environments. Some of these pressures include
hypoxia, presence of reactive oxygen species, or lack of
nutrients. Tumor cells must then alter their phenotype
in order to exist in environments with different selective
pressures [92].
In ovarian cancer, the “seed vs. soil” observation holds
true as the most common sites of metastasis are within
the peritoneal cavity. Mesothelial cells that express
mesothelin line the walls of the peritoneal cavity as well
as the organs within it. We and others have shown that
MUC16, present on the surface of cancer cells, binds
readily to mesothelin [93,94]. Recently, the binding site
for MUC16 on mesothelin was characterized [95]. This
interaction is just one of the many that make the “soil”
of mesothelial cells within the peritoneal cavity an
appropriate environment for ovarian cancer tumor cells.
In order to efficiently metastasize, tumor cells must
first detach from the primary tumor by downregulating
adhesive molecules, then later upregulate adhesive mole-
cules to attach again to the target site epithelium. The
initial step of detachment requires disruption of cell-cell
adhesions, and this is facilitated by a loss of E-cadherin.
E-cadherin is tethered to the actin cytoskeleton, which
plays a primary role in supporting cell-to-cell adhesions.
The disruption of the expression of E-cadherin can then
lead to cells which can disseminate from the primary
tumor. Loss of E-cadherin function is necessary but not
sufficient for an epithelial to mesenchymal cell type
transition [95]. Loss of E- cadherin has been seen in
many types of cancers, such as breast, prostate, esopha-
gus, stomach, colon, skin, kidney, lung, liver, and ovary
[96,97].
After detachment from the primary tumor site, the
next step of metastasis is to effectively invade into
neighboring tissues. Movement of the tumor cells
through solid tissues requires the acquisition of pheno-
types that allow cells to degrade the ECM and
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invade into these tissues [92].
Next, the tumor cells migrate into the circulation,
lymphatic system, or peritoneal space. In EOC, metasta-
sis is facilitated by the clockwise flow of peritoneal fluid.
The final steps of metastasis include arrest in the small
blood vessels of a distant organ, extravasation into the
surrounding tissue and proliferation at the secondary
site [92].
Immune Evasion
Patients with EOC often experience several periods of
remission and relapse of increasingly shortening periods
until their tumors become resistant to chemotherapeutic
treatment [98]. Additionally, as the stages of cancer pro-
gress, patients exhibit progressively deficient immune
responses, which indicate that the tumor has developed
mechanisms to subvert the immune response and sup-
press immune surveillance [99]. The importance of the
role of the immune system in the control and elimina-
tion of EOC is evidenced by a study that correlated the
5-year overall survival in EOC with the presence or
absence of tumor-infiltrating lymphocytes (TIL) (38% vs.
4.5%, respectively) [100]. There are several studies which
show that molecules from the tumor directly inhibit
immune cells. We have now also demonstrated that
MUC16 protects the ovarian tumor cells by sterically
blocking the NK cells from forming immune synapses
with the cancer cells [101]. High levels of shed MUC16
(sMUC16) are present in the PF of EOC patients and
this mucin binds to NK cells within the PF [76].
MUC16 binds specifically to the inhibitory receptor,
Siglec-9 on the surface of the NK cells (Belisle et al.,
paper submitted). Normally, NK cells in the peripheral
blood of healthy subjects have the phenotype 90% CD16
+ and 10% CD16
-.T h eC D 1 6
+ phenotype is associated
with activation and cytotoxicity, while the CD16
- cells
release cytokines and are not cytotoxic [102]. In the PF
of EOC patients, however, this ratio shifts to 60% CD16
+ and 40% CD16
-. Therefore, there are less cytotoxic
cells in the PF compared to the peripheral blood [76].
Other immune cell subsets can also be affected by fac-
tors within peritoneal fluid. A study published in 2001
described a factor within PF that induced the loss of the
T cell receptor (TcR)-associated signal transducing zeta-
chain (CD3ζ) [81]. They isolated this factor using col-
umn chromatography, gradient centrifugation, and mass
spectrometry and found that it was a 14 kD factor that
operated at the mRNA level [81]. Webb and colleagues
have shown that CD1d antigen presentation to NKT
cells is inhibited by factors within the PF. This effect
was dose dependent and CD1d specific [103]. Another
study determined that supernatants from ovarian cancer
cell lines inhibited CD8
+T cell proliferation and
function, as well as the cells’ ability to produce IFN-g.
IL-2R subunits g and b (but not a) were significantly
suppressed as measured by flow cytometry [104]. Our
group has also described the presence of Decoy Recep-
tor 3 (DcR3) in the peritoneal cavity of women with
advanced EOC and that this molecule functions as a
potent inhibitor of Fas-ligand mediated apoptosis a
common regulatory mechanism of the normal immune
system [80].
Tumor cells also produce ligands that can bind to
activating receptors on immune cells and thus downre-
gulate the expression of these receptors. The ligands for
activating receptor NKG2D are MHC class I-chain-
related proteins A and B (MICA/MICB) and the UL16-
binding proteins (ULBP-3) [105]. NKG2D ligands are
not expressed on normal, healthy cells and therefore the
expression of NKG2D ligands is correlated with malig-
nant transformation. NKG2D receptor is expressed by
all NK cells, CD8
+ T cells, most NKT cells, and a subset
of CD4
+ T cells [105]. When NKG2D binds to its
ligands, it induces the cytotoxic activation and prolifera-
tion of the immune cell. However, MICA and MICB
can be cleaved from tumor cells by tumor-associated
mellatoproteinases, which leads to soluble MICA and
MICB that can downregulate the expression of NKG2D
[106]. Wang and colleagues showed, using flow cytome-
try, that serum from prostate and ovarian cancer
patients contained high levels of soluble MICs and cor-
related increased soluble MIC expression with decreased
expression of NKG2D on T cells and a subset of NKT
cells in these patients [107]. Another study used immu-
nohistochemistry to determine that tumor from 82 ovar-
ian cancer patients showed expression of MICA, MICB,
and ULBP-2, while none of these molecules was
expressed by normal ovarian epithelium [108]. Strong
expression of ULBP-2 correlated with decreased infiltra-
tion of T cells and poor prognosis [108].
Immunotherapy In EOC
Most pre-clinical models of cancer immunotherapy indi-
cate that such treatments work best in the setting of
minimal volume, sub-clinical disease. Thus it is thought
that patients with minimal residual disease who clini-
cally appear to be in remission are ideal candidates for
immunotherapeutic strategies. Immunotherapies may
not be robust enough to eliminate the entire tumor
when used alone, however; their use after surgery and
chemotherapy may be useful to eliminate remaining
sub-clinical tumor cells to prevent recurrence. The high
rate of clinical response to therapy and the subsequent
high rate of recurrence in EOC after primary treatment
is evidence of a large number of women with sub-clini-
cal disease at the completion of therapy. These patients
may offer an excellent setting for immunotherapy.
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targeted to MUC16 as well as mesothelin. One such
immunotherapy, oregovomab, is an immunoglobulin (Ig)
I gG1k subclass murine monoclonal antibody that binds
with high affinity to circulating CA125. This antibody
complexes with CA125 and is taken up and processed
by APCs (antigen presenting cells) [109,110]. Both a
humoral and cellular response are produced, as demon-
strated by the production of CA125 specific antibodies,
T-helper cells, and CTLs in patients who received treat-
ment [109,111,112]. Survival was increased in patients
that mounted T-cell responses against CA125, however,
the most recent results from a phase III trial published
in January of 2009 stated that monoimmunotherapy
treatment with oregovomab resulted in no significant
difference in outcome compared to placebo [111].
Antibodies, designated 3A5 and 11D10, against the
tandem repeat sequence of MUC16 have been conju-
gated to the cytotoxic auristatin analogs monomethy-
lauristatin F and monomethylauristatin E [113,114].
These drug-conjugated antibodies have been utilized as
agents for chemotoxic immunotherapy resulting in an
improved therapeutic index against MUC16-expressing
OVCAR-3 tumors that were xenogenically grown in
mice [113].
Abagovomab (ACA125) is an anti-idiotypic antibody
against the MUC16 antibody OC125 and mimics the
antigenic epitope of MUC16. It serves as a surrogate
when given to patients. In phase I and II trials, patients
that received abagovomab antibody developed anti-anti-
idiotypic antibodies (Ab3) and this correlated with
increased survival [115,116]. Reinartz and colleagues
developed a fusion protein of ACA125 with interleukin
6 in order to stimulate ACA125 specific B cells [117].
This resulted in increased levels of Ab3 in patients who
received treatment.
Mesothelin is normally expressed by mesothelial cells
that line the pleura, peritoneum, and pericardium. It is
highly expressed by tumor cells associated with pancrea-
tic, ovarian, and lung adenocarcinomas as well as malig-
nant mesothelioma [118,119]. Its normal function is
unknown and knockout mice show no abormalities
[120]. However, we and others [93,94] have shown that
it binds to MUC16, which facilitates the metastasis of
ovarian cancer cells to the peritoneal cavity. Agents that
would inhibit this interaction would be beneficial to pre-
vent metastasis in EOC patients. A majority of patients
with serous epithelial ovarian cancer show increased
levels of serum mesothelin, making it a suitable target
for immunotherapies, considering its relatively low
expression in normal tissues [121]. SS1P is a recombi-
nant immunotoxin consisting of an anti-mesothelin Fv
linked to a Pseudomonas exotoxin that mediates cell
killing. Phase I trials have been completed with SS1P
and have shown anti-tumor activity in heavily treated
patients [122]. Pre-clinical studies in animal models
have shown that treatment with SS1P has an increased
effect when combined with chemotherapy [123].
MORAb-009 is a high affinity chimeric monoclonal
IgG1/ with high affinity and specificity for mesothelin
[124]. This antibody both induces ADCC (antibody-
dependent cellular cytotoxicity) against tumor cells that
express mesothelin as well as blocks the MUC16/
mesothelin interaction [124,125]. Phase I trials
with MORAb-009 are underway with 11 patients, 6 with
mesothelioma, 3 with pancreatic cancer, and 2 with
ovarian cancer. CRS-207 is another mesothelin cancer
vaccine that utilizes Listeria monocytogenes as the
vector. Pre-clinical studies have shown this vaccine to
elicit CD4
+/CD8
+ T cell mesothelin specific responses
in mice and cynomolgus monkeys. A Phase I trial for
CRS-207 is underway [123].
There are several other molecular candidates that are
being investigated for immunotherapy against ovarian
cancer. Incubation of immune cells with ovarian cancer
cells lead to generation of antigen specific T cells
against THP-1 and other peptide epitopes of ovarian
cancer [126]. Other potential antigens for immunother-
apy include p53, Her-2 and TPD52. Vaccination with
Her-2 peptides along with measles virus fusion protein,
a promiscuous T cell epitope causes increased anti-
tumor immune responses [127]. Similarly, 66% of mice
developing responses against TPD52 expressing prostate
tumors were free of the cancer 85 days after tumor
inoculation and were also able to resist a subsequent
tumor challenge [128]. The high expression of TPD52
by ovarian tumors provides hope that this strategy may
also provide benefit to ovarian cancer patients.
Autoantibodies against p53 are present in ovarian can-
cer patients and their presence is associated with
improved survival [129]. In a phase II clinical study,
patients vaccinated against specific p53 peptides showed
proliferation of p53 specific T cells [130]. These prolifer-
ating T cells were immune competent and produced
high levels of IFN-g. A subset of the patients (2/20;
10%) developing p53-specific T cells showed evidence of
stable disease as compared to the remaining cohort with
clinical and biochemical evidence of progressive disease.
T h e s ed a t ai n d i c a t et h a tm o r er e s e a r c hi sr e q u i r e dt o
produce effective immunotherapeutic approaches for the
treatment of ovarian tumors.
Conclusion
Cytoreductive surgery followed by intense chemotherapy
with platinum and taxol has become a standard
approach for the treatment of EOC. Therapy is espe-
cially effective if the cancer is detected at early stage of
progression. Future advances in the management and
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ment modalities and diagnostic tests that can accurately
detect early stage low volume tumors. While chemother-
apeutic approaches have been important in the manage-
ment of EOC, there is a growing sense in the field that
additional supportive therapeutic approaches will be
required for effective elimination of the cancer. The
polyclonal nature of EOC ensures that therapeutic
approaches may not eliminate the entire spectrum of
cancer cells present in a patient. Combinatorial
approaches that can result in direct cytotoxicity, prevent
tumor angiogenesis, inhibit cancer metastasis, and also
simultaneously increase the immunologic detection of
tumors may be required to eliminate the polyclonal
tumors. Such a holistic approach will require delineation
of the molecular mechanisms that allow tumors to
metastasize, promote angiogenesis, and to circumvent
any effective immunological responses.
The combined treatment strategies will benefit from
the development of diagnostic and screening tests. To
date the “gold standard” for assessing the regression
and recurrence of EOC is the serum CA125 (MUC16)
assay. However, this assay is limited in its scope. Devel-
opment of novel proteomics based approaches for the
development of diagnostic tests hold great promise.
However, even after intense research, successful devel-
opment of a proteomics-based diagnostic test has
remained elusive.
Overall, significant hurdles still remain in the effective
diagnosis and treatment of EOC. The significant
advances made in the molecular understanding of EOC,
development of murine models and novel proteomics-
based technologies, and the use of immune-based treat-
ment approaches are likely to provide novel opportu-
nities for the effective management of EOC.
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